Krsnaa Diagnostics Ltd has fixed a price band of Rs 933-954 a share for its initial public offer (IPO). The IPO will open for subscription on 4 August and close on 6 August.
The IPO will consist of a fresh issue of Rs 400 crore and an offer for sale of up to 8.53 million shares by its existing promoters and shareholders.
At the upper end of the issue price, the firm will raise approximately Rs 1213.76 crore.
The OFS comprises sale of 1.6 million shares by PHI Capital Trust-PHI Capital Growth Fund-I, up to 3.34 million shares by Kitara PIIN 1104, up to 3.56 million shares by Somerset Indus Healthcare Fund I Ltd and up to 21,380 shares by Lotus Management Solutions.
JM Financial Ltd, DAM Capital Advisors Ltd, Enquires Capital Pvt and IIFL Securities are the book-running lead managers to the issue.
The proceeds from the issue of Rs 150.81 crore will be used for financing the cost of establishing diagnostics centers at Punjab, Karnataka, Himachal Pradesh and Maharashtra.
The firm will use Rs 125.70 crore for repayment of certain borrowings availed by it. As of June 2021, the total debt under the various financing arrangements of the company aggregated to Rs141.73 crore.
For fiscal year 2021, the total income of the company stood at Rs 661.48 crore versus Rs 271.38 crore a year ago. Net profit for the period stood at Rs 184.93 crore against a net loss of Rs 111.95 crore last year.
Number''s speak true story and listing gain is definitely on the table. But devyani has a better brand value and long term bet than this.But who cares most of us here are for listing gains.
Its still a loss making company. if we remove 1 time Gain on fair value 250Cr from income then FY21 loss will be 70cr. By altering P&L statement just trying to fool investors with such high valuations for loss making companies
Keep everything aside and look at operating profits. And the FY21 fair value gain that you are talking about, the counter-entry is what actually caused loss in prior years.
In terms of revenue CAGR they are far above peers (refer RHP Pg 136), and in operating margin they are in top 3.
If I keep that fair value gain a side, after I gone through RHP found that this company is unique in diagnostics space that''s why some demand in grey market.
Growing at very fast rate as compared to any one in industry. One should hold it for longterm if allotted. Don''t be hurry in selling.
To. Addmin ji Please update BOOK PRECE ABD ALL OTHERS NESESORY INFORMATION LIKE ALOCATION % QUITA BIFERCATION QIB HNI RETAIL ABE STAF. FOR ALL COMPANEY SEPRATE BOX THANKS
Last years revenue and profits are due to covid, future is uncertain...but again GMP will make things interesting. Out of 4 if you leave devyani out of the picture, there''s good probability of profit & allotment in HNI category. Just like kims...🔥